^
Association details:
Biomarker:ERBB4 G1109C
Cancer:Esophageal Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Excerpt:
Two cell lines, KYSE270 and SAS, were hypersensitive to afatinib (Fig. 1A and B). In contrast, none of the cell lines were sensitive to cetuximab or erlotinib….KYSE270 cell lines harbored an EGFR L861Q mutation and that the SAS cell line harbored an HER4 G1109C mutation, respectively...
DOI:
10.1158/1535-7163.MCT-15-0737